Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.

Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T, Chuah E, Corbett R, Fejes AP, Griffith M, Yee J, Martin M, Mayo M, Melnyk N, Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliffe M, Tam A, Terry J, Thiessen N, Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG, Birol I, Hirst M, Holt RA, Marra MA.

Genome Biol. 2010;11(8):R82. doi: 10.1186/gb-2010-11-8-r82. Epub 2010 Aug 9.

PMID:
20696054
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
[PubMed - indexed for MEDLINE]
3.

Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.

Sulkes A.

Isr Med Assoc J. 2010 Oct;12(10):628-32. Review.

PMID:
21090521
[PubMed - indexed for MEDLINE]
Free Article
4.

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.

Lin CI, Whang EE, Lorch JH, Ruan DT.

Surgery. 2012 Dec;152(6):1142-9. doi: 10.1016/j.surg.2012.08.016.

PMID:
23158184
[PubMed - indexed for MEDLINE]
5.

In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.

Prazeres H, Couto JP, Rodrigues F, Vinagre J, Torres J, Trovisco V, Martins TC, Sobrinho-Simões M, Soares P.

Endocr Relat Cancer. 2011 Jul 1;18(4):401-12. doi: 10.1530/ERC-10-0258. Print 2011 Aug.

PMID:
21551259
[PubMed - indexed for MEDLINE]
Free Article
6.

Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.

Suzuki M, Makinoshima H, Matsumoto S, Suzuki A, Mimaki S, Matsushima K, Yoh K, Goto K, Suzuki Y, Ishii G, Ochiai A, Tsuta K, Shibata T, Kohno T, Esumi H, Tsuchihara K.

Cancer Sci. 2013 Jul;104(7):896-903. doi: 10.1111/cas.12175. Epub 2013 May 12.

PMID:
23578175
[PubMed - indexed for MEDLINE]
7.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
[PubMed - indexed for MEDLINE]
8.

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.

Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH.

J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5.

PMID:
20368568
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

KIF5B-RET fusions in lung adenocarcinoma.

Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T.

Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.

PMID:
22327624
[PubMed - indexed for MEDLINE]
10.

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.

Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, Jänne PA, Stephens PJ.

Nat Med. 2012 Feb 12;18(3):382-4. doi: 10.1038/nm.2673.

PMID:
22327622
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.

Broutin S, Ameur N, Lacroix L, Robert T, Petit B, Oumata N, Talbot M, Caillou B, Schlumberger M, Dupuy C, Bidart JM.

Clin Cancer Res. 2011 Apr 1;17(7):2044-54. doi: 10.1158/1078-0432.CCR-10-2041. Epub 2011 Feb 15.

PMID:
21325074
[PubMed - indexed for MEDLINE]
Free Article
12.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
[PubMed - indexed for MEDLINE]
13.

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC.

Curr Cancer Drug Targets. 2011 Oct;11(8):944-53.

PMID:
21834756
[PubMed - indexed for MEDLINE]
14.

Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.

Leung HW, Chan AL.

Clin Ther. 2011 Jun;33(6):708-16. doi: 10.1016/j.clinthera.2011.05.003.

PMID:
21704235
[PubMed - indexed for MEDLINE]
15.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
[PubMed - indexed for MEDLINE]
16.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

PMID:
15240784
[PubMed - indexed for MEDLINE]
Free Article
17.

The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.

Sawai H, Okada Y, Kazanjian K, Kim J, Hasan S, Hines OJ, Reber HA, Hoon DS, Eibl G.

Cancer Res. 2005 Dec 15;65(24):11536-44.

PMID:
16357163
[PubMed - indexed for MEDLINE]
Free Article
18.

Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.

Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R.

Mol Cancer Ther. 2008 May;7(5):1001-6. doi: 10.1158/1535-7163.MCT-07-2422. Epub 2008 Apr 29.

PMID:
18445656
[PubMed - indexed for MEDLINE]
Free Article
19.

The transcriptional landscape and mutational profile of lung adenocarcinoma.

Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT.

Genome Res. 2012 Nov;22(11):2109-19. doi: 10.1101/gr.145144.112. Epub 2012 Sep 13.

PMID:
22975805
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS.

Genome Res. 2012 Mar;22(3):436-45. doi: 10.1101/gr.133645.111. Epub 2011 Dec 22.

PMID:
22194472
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk